使用观察性纵向数据评价依泊苷给药策略
Evaluating epoetin dosing strategies using observational longitudinal data
摘要:
依泊苷通常用于治疗接受透析的慢性肾病和终末期肾病受试者的贫血,然而,对于这些受试者的血红蛋白或红细胞压积目标水平存在相当大的不确定性。为了解决这个问题,我们将依泊苷给药指南视为一种动态治疗方案。具体来说,我们提出了一种使用观察数据比较替代治疗方案对生存期影响的方法。在随机试验中,患者可以被分配遵循特定的管理指南,但在观察性研究中,受试者可能有同时遵守多种方案的治疗路径。我们提出了一种克隆策略,其中每个受试者都对每个治疗方案提供随访数据,这些治疗方案是连续遵守的,并在第一次不遵守时进行人工删失。我们详细介绍了一个逆概率加权对数秩检验与一个有效的渐近方差估计,可用于测试两种方案下的生存分布。为了比较多个方案,我们提出了几个边际结构考克斯比例风险模型与强大的方差估计,以考虑克隆的创建。该方法通过模拟来说明,并应用于比较来自美国肾脏数据系统的33,873例成人血液透析患者队列中的依泊苷给药方案的分析。
英文摘要:
Epoetin is commonly used to treat anemia in chronic kidney disease and End Stage Renal Disease subjects undergoing dialysis, however, there is considerable uncertainty about what level of hemoglobin or hematocrit should be targeted in these subjects. In order to address this question, we treat epoetin dosing guidelines as a type of dynamic treatment regimen. Specifically, we present a methodology for comparing the effects of alternative treatment regimens on survival using observational data. In randomized trials patients can be assigned to follow a specific management guideline, but in observational studies subjects can have treatment paths that appear to be adherent to multiple regimens at the same time. We present a cloning strategy in which each subject contributes follow-up data to each treatment regimen to which they are continuously adherent and artificially censored at first nonadherence. We detail an inverse probability weighted log-rank test with a valid asymptotic variance estimate that can be used to test survival distributions under two regimens. To compare multiple regimens, we propose several marginal structural Cox proportional hazards models with robust variance estimation to account for the creation of clones. The methods are illustrated through simulations and applied to an analysis comparing epoetin dosing regimens in a cohort of 33,873 adult hemodialysis patients from the United States Renal Data System.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。